Back to top
more

Vertex Pharmaceuticals (VRTX)

(Real Time Quote from BATS)

$477.88 USD

477.88
259,371

-3.38 (-0.70%)

Updated Sep 18, 2024 01:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.

Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down

by Zacks Equity Research

Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.

The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals

Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal

by Zacks Equity Research

Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

by Zacks Equity Research

We expect CRISPR (CRSP) to provide updates on its pipeline candidates in the third quarter of 2018.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.

Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 9.00% and 0.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT

by Zacks Equity Research

Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.

Is a Beat in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research

On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings?

by Zacks Equity Research

Anika Therapeutics (ANIK) is scheduled to report third-quarter earnings on Oct 24.

Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research

Bristol-Myers (BMY) is scheduled to report third-quarter earnings on Oct 25.

Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CELG vs. VRTX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CELG vs. VRTX: Which Stock Is the Better Value Option?

J&J (JNJ) to Set the Ball Rolling for Pharma Q3 Earnings

by Zacks Equity Research

The positive trend seen in J&J's (JNJ) pharma segment sales is likely to continue in the third quarter.

Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)

by Zacks Equity Research

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

3 Biotech Stocks With Rising Estimates in the Past Month

by Zacks Equity Research

The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.

    Ryan McQueeney headshot

    Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch

    by Ryan McQueeney

    Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.

      Lilly (LLY) Hits 52-Week High, Can the Run Continue?

      by Zacks Equity Research

      Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

        Vertex Completes Enrollment in Triple Combination Studies

        by Zacks Equity Research

        Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.

          Kinjel Shah headshot

          Lilly, Teva, Pfizer & Others Await FDA Decisions in September

          by Kinjel Shah

          FDA grants approval to 34 new treatments this year so far.

            The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

            by Zacks Equity Research

            The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

              Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars

              by Zacks Equity Research

              Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.

                Vertex Inks Reimbursement Agreement for Orkambi in Australia

                by Zacks Equity Research

                Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.

                  Vertex Inks Deal With Genomics to Make Serious Disease Drugs

                  by Zacks Equity Research

                  Vertex (VRTX) signs a three-year collaboration contract with Genomics to develop novel drug targets for advancing discovery of precision medicines.